| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 115.3 | 92.0 | 46.8 |
| Other income | 0.9 | 0.2 | 0.7 |
| Total income | 116.1 | 92.2 | 47.5 |
| Profit before exceptional items & tax | 26.2 | 1.0 | 2.4 |
| Profit before tax | 26.2 | 1.0 | 2.4 |
| Net profit | 21.1 | 1.8 | 1.8 |
| Operating margin | 22.6% | 1.1% | 5.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1072.20% |
|---|---|
| Net profit, quarter on quarter | +1072.20% |
| Revenue, year on year | +146.40% |
| Operating profit, year on year | +1388.20% |
| Operating profit, quarter on quarter | +3062.50% |
NSE results filing, NSE: VALIANTLAB. Figures extracted from the filing.
Valiant Laboratories Ltd: key numbers
- Share price
- ₹124.87
- Market cap
- ₹678.2 Cr
- Revenue (annual)
- ₹237.5 Cr
- Net profit (annual)
- ₹-3.27 Cr
- P/E (TTM)
- 42.4×Sector 50.4×
- Promoter holding
- 74.94%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Valiant Laboratories Ltd
All →Valiant Laboratories Acquisition Worth ₹0.7 Cr
Valiant Laboratories approved acquiring up to 1.01% equity in AMPYR Renewable Energy for ₹0.70 Crore. The investment enables captive solar power for its Tarapur plant.
- Value
- ₹0.70 Cr
- Execution
- 12 months from date of board approval
Valiant Laboratories Credit Rating
Valiant Laboratories Limited received a credit rating of IND BBB/Stable/IND A2 from India Ratings and Research for bank loan facilities totaling INR 56 Crore.
- Value
- ₹56.00 Cr
Valiant Laboratories Other Announcement
Valiant Laboratories Limited has dispatched letters to shareholders who have not registered their email addresses, providing access to the Annual Report and 5th AGM notice.
Valiant Laboratories Annual General Meeting
Valiant Laboratories Limited issued a notice for its Annual General Meeting scheduled for September 28, 2026, covering financial adoption, director appointments, and related party transaction approvals.
Valiant Laboratories Annual Report
Valiant Laboratories Limited has filed its Annual Report for the financial year 2025-26, including the notice of its 5th Annual General Meeting.
Valiant Laboratories Q4 FY26 Results: Net Profit ₹1.8 Cr, Up 157.1% YoY
Valiant Laboratories Ltd reported revenue from operations of ₹92 Cr (+59.2% YoY) and net profit of ₹1.8 Cr (+157.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹1.8 Cr · +157.1% YoY